跳转至内容
Merck
CN

UC177

Sigma-Aldrich

(±)-Mephenytoin

别名:

(±)-5-Ethyl-3-methyl-5-phenyl-2,4-imidazolidinedione, (±)-5-Ethyl-3-methyl-5-phenylhydantoin

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C12H14N2O2
CAS号:
分子量:
218.25
EC 号:
MDL编号:
UNSPSC代码:
12161501
PubChem化学物质编号:

表单

crystals

质量水平

颜色

off-white

mp

115-118 °C
135-137 °C

溶解性

DMSO: soluble

储存温度

2-8°C

SMILES字符串

CCC1(NC(=O)N(C)C1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)

InChI key

GMHKMTDVRCWUDX-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

CYP2B6 and CYP2C19 substrate; anticonvulsive, antiepileptic.

包装

Bottomless glass bottle. Contents are inside inserted fused cone.

制备说明

(±)-Mephenytoin is soluble in DMSO.

象形图

Exclamation mark

警示用语:

Warning

危险分类

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Doaa A Elsherbiny et al.
Journal of pharmacokinetics and pharmacodynamics, 35(2), 203-217 (2008-03-20)
The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. The population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, including enzyme turn-over models for induction
Susanne Löfgren et al.
Drug metabolism and disposition: the biological fate of chemicals, 36(5), 955-962 (2008-02-16)
CYP2C19 is an important enzyme for human drug metabolism, and it also participates in the metabolism of endogenous substrates, whereas the CYP2C18 enzyme is not expressed in human liver despite high mRNA expression. Mice transgenic for the human CYP2C18 and
Huijuan Wang et al.
Drug metabolism and disposition: the biological fate of chemicals, 39(5), 830-837 (2011-02-18)
CYP2C19 is a highly polymorphic enzyme that affects the metabolism of a wide range of therapeutic drugs. Almost all the identified alleles of CYP2C19 are derived from nonsynonymous single nucleotide polymorphisms (nsSNPs). The objective of this study was to functionally
Michael Zientek et al.
Journal of pharmacological and toxicological methods, 58(3), 206-214 (2008-07-19)
Inhibition of cytochrome P450 (CYP) is a principal mechanism for metabolism-based drug-drug interactions (DDIs). This article describes a robust, high-throughput CYP-mediated DDI assay using a cocktail of 5 clinically relevant probe substrates with quantification by liquid chromatography/tandem mass spectrometry (LC/MS-MS).
Yajing Hu et al.
Pharmacogenetics and genomics, 23(2), 78-83 (2012-12-18)
We investigated whether human pharmacogenetic factors could be characterized using chimeric NOG mice expressing a thymidine kinase transgene (TK-NOG) with 'humanized' livers. The rate of human-specific metabolism of two drugs was measured in chimeric mice reconstituted with human hepatocytes with

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门